Kolexia
Belhadj-Merzoug Karim Médecine générale
Belhadj-Merzoug Karim
Médecine générale
Hôpital Henri Mondor
Créteil, France
209 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Lymphomes Tumeurs à plasmocytes Lymphome B Lymphome B diffus à grandes cellules Amyloïdose Translocation génétique Amylose à chaine légère d'immunoglobuline Lymphome B de la zone marginale

Collaborateurs

Voir plus
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Karlin Lionel
Karlin Lionel
Hôpital Lyon Sud, Pierre-Bénite, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France

Industries

Voir plus
Janssen
52 collaboration(s)
Dernière en 2023
M3 Global Research Ltd
25 collaboration(s)
Dernière en 2021
Sanofi
24 collaboration(s)
Dernière en 2023
A+A
16 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
KarMMa-9: A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Essai Clinique (BMS)   18 mars 2024
Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.
ESC heart failure   05 mars 2024
Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series.
Blood   14 décembre 2023
Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.
Thrombosis research   02 décembre 2023
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01
65th ASH Annual Meeting Abstracts   02 novembre 2023
Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
65th ASH Annual Meeting Abstracts   02 novembre 2023
Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
65th ASH Annual Meeting Abstracts   02 novembre 2023
Real-World Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated before the Anti-CD38 Antibodies Era in France, the Emmy Cohort 2017 to 2020
65th ASH Annual Meeting Abstracts   02 novembre 2023
Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status in Anti-CD38-Naïve Population
65th ASH Annual Meeting Abstracts   02 novembre 2023
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
Frontiers in oncology   02 novembre 2023